Coverage
-
October 13, 2020
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating an Amgen unit's patent on treating inflammatory disorders, in a win for Sanofi and Regeneron, whose eczema and asthma treatment Dupixent was accused of infringement.
1 other articles on this case.
View all »